Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Salmon calcitonin is a synthetically produced 32-amino-acid peptide hormone that corresponds to the body's own calcitonin but exhibits higher biological potency than the human hormone. In the scientific literature it is studied in the context of inhibiting osteoclast-mediated bone resorption and lowering elevated calcium levels. It was historically broadly approved for the treatment of postmenopausal osteoporosis; following European safety reviews, however, its use was restricted.
Researched for
Paget's disease of boneTumor-associated hypercalcemiaAcute bone loss due to immobilizationPain from acute vertebral fracturesPostmenopausal osteoporosis (historical)
Official status
US: Prescription
In the United States, salmon calcitonin is approved as a prescription medicine (including the injectable Miacalcin and, historically, the nasal spray Miacalcin/Fortical). Indications include Paget's disease, tumor-associated hypercalcemia, and historically postmenopausal osteoporosis; the nasal spray products have in part been discontinued. The FDA has noted the possible cancer risk observed in studies.
Salmon calcitonin binds the calcitonin receptor, which is particularly densely expressed on bone-resorbing osteoclasts. The literature describes that receptor activation inhibits osteoclast activity and motility, thereby reducing bone resorption. This results in reduced release of calcium and phosphate from bone into the blood, which is regarded as the mechanistic basis for the calcium-lowering effect. The salmon variant binds the receptor more strongly and for longer than human calcitonin, which explains its higher potency. Central nervous system mechanisms are additionally discussed in relation to its pain effect in fractures, the basis of which is regarded in the literature as not fully elucidated.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · 2 tiers
Human RCT
2
Human trial
2
03
What the studies show
Human trial
Mensch
Singer FR et al. 1991
Reduction of bone-turnover markers and clinical efficacy in Paget's disease of bone, including lowering of elevated alkaline phosphatase levels.
What does NOT follow: A proportion of treated individuals develops neutralizing antibodies against the salmon peptide, which can attenuate the effect over time; the data derive from older clinical literature and are not transferable to other indications.
Human RCT
Mensch
Chesnut CH 3rd et al. 2000
In a large randomized trial, a lower incidence of new vertebral fractures was reported in postmenopausal women with established osteoporosis under one of the studied dosing arms of the intranasal preparation.
What does NOT follow: The trial showed no consistent dose-response relationship (only one intermediate arm reached statistical significance) and had a high dropout rate; its informative value is therefore considered limited. Due to later safety reviews, this indication is no longer supported in Europe.
Human RCT
Mensch
Knopp JA et al. 2005
Short-term relief of pain in acute osteoporotic vertebral compression fractures across several small controlled trials.
What does NOT follow: The pooled evidence rests on few small trials of limited methodological quality and short follow-up (about four weeks); a long-term or broadly generalizable conclusion cannot be drawn from it.
Human trial
Mensch
Wells G et al. 2016
In long-term analyses of clinical trials, a numerically slightly higher occurrence of malignancies was observed under calcitonin compared with placebo, which led to regulatory restrictions.
What does NOT follow: A later review and meta-analysis judged the association to be weak and a causal relationship unlikely; a residual risk could nonetheless not be entirely excluded. This is a statistical signal from pooled trials, not a proven mechanism of harm.
04
Where studies disagree
Open question
Does long-term use of calcitonin increase the risk of cancer?
POSITION A
Regulatory analyses of pooled long-term trials showed a numerically slightly higher occurrence of malignancies under calcitonin versus placebo, which led to use restrictions.
POSITION B
A later review and meta-analysis judged the association weak, biological plausibility low, and a causal relationship unlikely.
CURRENT STATE · Regulatory precautions (particularly restriction of long-term and nasal-spray use in Europe) remain in place, while the strength of any causal relationship is regarded in the literature as uncertain and probably small.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 1 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
In clinical trials and approved use, salmon calcitonin is administered parenterally, including subcutaneously. This statement describes the documented trial and approval context and does not constitute a usage instruction.
Intranasal
Historically, salmon calcitonin was also studied and marketed as a nasal spray, particularly in osteoporosis trials. This form was restricted, and in part withdrawn, for the osteoporosis indication following regulatory safety reviews. Context only, not a usage instruction.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human trial
In long-term analyses of clinical trials, a slightly higher occurrence of malignancies was observed under calcitonin compared with placebo; the European Medicines Agency quantified the difference at roughly 0.7% to 2.4% higher frequency, with the higher figures seen in trials of the intranasal form.
This is a statistical signal from pooled trials; a later meta-analysis judged a causal relationship unlikely but could not fully exclude it. No statement about an individual's risk.
Human trial
With the intranasal formulation, local nasal mucosa reactions (e.g., irritation, dryness, nosebleed) were reported in studies; with parenteral administration, nausea, flushing, and injection-site reactions.
Frequency and severity are derived from controlled trial populations and cannot be directly extrapolated to individuals.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
09
Regulatory voices
Direct statements from official assessment documents — paraphrased with date and source link.
EMAEuropean Medicines Agency
2012-07-20
CHMP recommendation to limit long-term use of calcitonin-containing medicines following evaluation of the cancer-risk signal (20 July 2012).
In long-term clinical trials the risk of developing cancer was 0.7% to 2.4% higher in patients receiving calcitonin-containing medicines compared to those patients receiving placebo.
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Calcitonin (salmon) was once a common osteoporosis option but is rarely recommended today.
historical context, reflected in patient forums
Not supported by studies: The background is comparatively weak efficacy plus a cancer-risk signal observed in long-term analyses — a report of the regulatory assessment, not a usage instruction.
10b
What online communities discuss
Recurring themes from Reddit, Quora and patient forums — synthetically summarised, sources linked. Not scientific evidence, but a signal of what users report. Deliberately separated from the study base.
Non-scientific sources. What users report in forums — synthetically summarised, paraphrased, with link to source. Not validated by studies.
Sorted by discussion frequency · 1 Thema
Discussion frequency: ~83 aggregated reviews
On drugs.com, calcitonin (salmon, Miacalcin nasal spray) is rated strikingly low: around 2.7 out of 10 across roughly 83 reviews. Recurring mentions are nausea, fatigue and lack of effect; isolated positive reports concern pain relief after vertebral fractures.
What this does NOT mean:Review platforms are self-selected, unblinded and not representative; the figures are a snapshot (as of June 2026). They do not replace controlled data — see the studies section. The low rating aligns with its cautious guideline role today: regulators point to an increased cancer-risk signal seen in pooled analyses and limited efficacy, which is why use was restricted.
In the United States, salmon calcitonin is approved as a prescription medicine (including the injectable Miacalcin and, historically, the nasal spray Miacalcin/Fortical). Indications include Paget's disease, tumor-associated hypercalcemia, and historically postmenopausal osteoporosis; the nasal spray products have in part been discontinued. The FDA has noted the possible cancer risk observed in studies.
2026-06-07
Germany
Prescription
In Germany, salmon calcitonin is prescription-only. Following a 2012 assessment by the European Medicines Agency (EMA), its use was restricted: the nasal spray formulation for treating osteoporosis was no longer recommended due to an unfavorable benefit-risk balance, and use should be limited to short periods. Remaining indications are injectable forms for Paget's disease, acute bone loss due to immobilization, and tumor-associated hypercalcemia.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group